New Class III Antiarrhythmic Drugs for Treatment of Atrial Fibrillation

Last two decades have been dedicated to intensive search for new class III antiarrhythmic drugs, especially for atrial fibrillation. Here we present a review of the status this problem. Influence on transmembranous ion currents and mechanisms of antiarrhythmic action are described. Results of experimental and clinical studies are reviewed. Possible perspectives of newest atrial-selective medications are discussed. Russia's class III antiarrhythmic drugs are of special interest of the article. First data on efficacy and safety of newest agent niferidil are presented. This drug undergoes clinical testing at present time.